Devonian Health Group is trading 10% down at CA$6.75, with no verified company-specific news explaining the decline.
- Shares fell from the October 27 close of CA$7.50.
- An October 28 report covered Health Canada authorization for a pediatric Thykamine trial but did not link it to the share-price drop.
- The broader biotech sector is higher; with no clear catalyst or confirmed trading-volume details, the reason for the decline remains uncertain.